Tag Archives: Xiaolin Qi

Acoustofluidics for intracellular nanoparticle delivery?

Caption: (a) Device schematic. (b) Cross-sectional view of the device for illustrating the generation of standing bulk acoustic waves with a pressure node at the top capillary wall, which can push a cell loaded in the capillary to the top wall. (c) Illustration of the cell movement in a capillary coated with cargo-encapsulated nanoparticles under continuous flow and acoustic waves. The acoustic waves can push cells to the top wall, enabling controllable contact between cells and nanoparticles when the cells flow through the capillary along its top wall. (d) A schematic illustrating the intracellular cargo delivery process. Credit: Zhishang Li et al.

A June 18, 2025 news item on Nanowerk announces a new approach to delivering nanoparticles for therapeutic applications and more, Note: A link as been removed,

Scientists demonstrate an innovative acoustofluidics-based approach for intracellular nanoparticle delivery. This method offers a new way to transport various functional nanomaterials into different cell types, potentially revolutionizing therapeutic applications and biophysical studies.

A recent study published in Engineering (“Acoustofluidics-Based Intracellular Nanoparticle Delivery”) presents an innovative acoustofluidics-based approach for intracellular nanoparticle delivery. This method offers a new way to transport various functional nanomaterials into different cell types, potentially revolutionizing therapeutic applications and biophysical studies.

This is the same news release but there are two different issuing dates and two different issuing agencies. A March 7, 2025 Higher Education Press news release on EurekAlert and an identical June 18, 2025 Engineering Fronts news release on Newswise, which appear to have originated the information in the news item on Nanowerk, offer more details, Note: Links have been removed

The efficient delivery of biomolecular cargos into cells is crucial for biomedical research, including gene therapies and drug delivery. However, traditional delivery methods such as endocytosis of nano-vectors, microinjection, and electroporation have limitations. They may require time-consuming processes, complex operations, or expensive equipment. Additionally, issues like low delivery efficiency and potential cell damage still exist.

The newly developed acoustofluidics-based method addresses these challenges. It uses standing acoustic waves generated in a glass capillary coated with cargo-encapsulated nanoparticles. By tuning the frequency of the acoustic waves, cells flowing through the capillary are pushed towards the capillary wall. This enables controllable contact between cells and nanoparticles, facilitating nanoparticle attachment to the cell membrane. The acoustic radiation force also increases membrane stress, which slightly deforms the cells and enhances membrane permeability, helping nanoparticles enter the cells.

In the study, researchers used two types of cargos, doxorubicin (DOX) and fluorescein isothiocyanate (FITC)-labeled bovine serum albumin (FBSA), to test the method. They loaded these cargos into zeolitic imidazolate framework-8 (ZIF-8) nanoparticles. The results showed that the method could successfully deliver nanoparticles loaded with different cargos into U937 and HeLa cells. The delivery efficiency was significantly enhanced compared to approaches without using acoustofluidics. What’s more, this method does not need bubbles or special acoustic contrast agents, which are often required in conventional sonoporation methods.

The researchers also investigated the properties of the cargo-encapsulated ZIF-8 nanoparticles and the impact of the delivery process on cell viability. They found that the nanoparticles had suitable characteristics for cargo encapsulation and release, and the acoustic waves and ZIF-8 decomposition had minimal effects on cell viability.

This acoustofluidics-based intracellular delivery approach provides a new option for achieving efficient and controllable intracellular delivery of biomolecular cargos. In the future, the research team plans to explore its application in delivering other types of cargo and in treating different cell types, including primary human cells. The findings of this study have the potential to contribute to the development of gene and cellular therapies, as well as fundamental research in cell mechanics.

The paper “Acoustofluidics-Based Intracellular Nanoparticle Delivery,” authored by Zhishang Li, Zhenhua Tian, Jason N. Belling, Joseph T. Rich, Haodong Zhu, Zhehan Ma, Hunter Bachman, Liang Shen, Yaosi Liang, Xiaolin Qi, Liv K. Heidenreich, Yao Gong, Shujie Yang, Wenfen Zhang, Peiran Zhang, Yingchun Fu, Yibin Ying, Steven J. Jonas, Yanbin Li, Paul S. Weiss, and Tony J. Huang. Full text of the open access paper: https://doi.org/10.1016/j.eng.2024.11.030. For more information about the Engineering, follow us on X (https://twitter.com/EngineeringJrnl) & like us on Facebook (https://www.facebook.com/EngineeringJrnl).

A little repetitive but here’s a link to and a citation for the paper anyway,

Acoustofluidics-Based Intracellular Nanoparticle Delivery by Zhishang Li, Zhenhua Tian, Jason N. Belling, Joseph T. Rich, Haodong Zhu, Zhehan Ma, Hunter Bachman, Liang Shen, Yaosi Liang, Xiaolin Qi, Liv K. Heidenreich, Yao Gong, Shujie Yang, Wenfen Zhang, Peiran Zhang, Yingchun Fu, Yibin Ying, Steven J. Jonas, Yanbin Li, Paul S. Weiss, Tony J. Huang. Engineering Volume 47, April 2025, Pages 130-138 DOI: https://doi.org/10.1016/j.eng.2024.11.030 Available online 14 December 2024, Version of Record 23 April 2025. Creative Commons Licence: Attribution-NonCommercial-No Derivatives 4.0 International

This paper is open access.

First-of-its-kind eyedrops use synthetic nanoparticles to help eye regenerate cells

Northwestern Medicine investigators have developed first-of-its-kind eyedrops that use synthetic nanoparticles to help the eye regenerate cells that have been damaged by mustard keratopathy, or exposure to mustard gas, and other inflammatory eye diseases. Image by Mark E. Seniw Courtesy: Northwestern University

A May 11, 2025 news item on statnano.com announces a regenerative medicine story focused on healing damaged corneas, Note: A link has been removed,

Northwestern Medicine investigators have developed first-of-its-kind eyedrops that use synthetic nanoparticles to help the eye regenerate cells that have been damaged by mustard keratopathy, or exposure to mustard gas, and other inflammatory eye diseases, detailed in a recent study published in the journal NPJ Regenerative Medicine.

Limbal epithelial stem cells are responsible for maintaining and regenerating the cornea’s epithelium, the outermost layer of the cornea. The loss or dysfunction of these cells can lead to limbal stem cell deficiency (LSCD), which can in turn cause persistent breakdown of the corneal epithelium and, eventually, blindness.

The disorder can be caused by genetic mutations but also chronic inflammation and severe external injuries, including the exposure to sulfur mustard or mustard gas, which has been historically used during wartime.

Topical corticosteroids have commonly been used to treat inflammation preceding LCSD. However, adverse side effects from long-term steroid use can occur and often steroids do not promote wound repair.

In response to an urgent need for new targeted therapies, investigators created novel restoring eyedrops containing synthetic lipoprotein nanoparticles developed in Thaxton’s [Shad Thaxton, professor of Urology] laboratory.

A May 7, 2025 Northwestern University news release (available on the university’s Feinberg News Center site and on the university’s Center for Regenerative Medicine news site) by Melissa Rohman, which originated the news item, provides more details, Note: Links have been removed,

These nanoparticles were designed to mimic some properties of a specific type of lipoprotein called high-density lipoproteins (HDLs), which are naturally found in the bloodstream and can help the body regulate many functions, including inflammation.  

“By taking a page out of nature’s playbook, we could begin to synthesize these types of materials and be able to control their sizes, shapes and compositions so that we can take advantage of some of their most beneficial properties such as reducing inflammation,” said Thaxton, an associate professor of Urology at Northwestern and co-senior author of the study.

“The therapeutic possibilities of these materials are tremendous as they can also be programmed to carry a broad range of active drugs that work synergistically with the native wound-healing ability of the HDL nanoparticles,” said SonBinh Nguyen, professor of Chemistry in the Weinberg College of Arts and Sciences and co-senior author of the study.

The investigators then administered the eyedrops to mice with different phases of nitrogen mustard cornea injury, an experimental model developed by Han Peng, associate professor of Dermatology and co-senior author of the study. Mice with acute inflammation received eyedrops daily for three days and mice with chronic, long-term injury received eyedrops daily for 14 days.

Using advanced imaging techniques and PCR analysis, the scientists discovered the eyedrops not only reduced inflammation in the eyes of the mice but also restored damaged limbal epithelium, which enabled the cornea to essentially heal itself and recover.

“This is the first time that this type of reversal of LSCD has been shown,” said Robert Lavker, Professor Emeritus of Dermatology and co-senior author of the study.

The findings demonstrate how the novel eyedrops could be a promising treatment not only for mustard keratopathy but also for other inflammatory corneal diseases, such as bacterial keratitis, alkali burns and dry eye.

“To our knowledge, this is the first demonstration of a topical therapy that can resolve ocular inflammation, conjunctivalization and corneal stromal neovascularization. With the myriad of diseases having a component of LSCD, we believe that the nanoparticles have broad therapeutic potential,” the authors wrote.

Timothy Feliciano, an MD/PhD student in the Medical Scientist Training Program (MSTP), and Elif Kayaalp Nalbant, a postdoctoral fellow in the Department of Dermatology, were co-first authors of the study.

Co-authors include Jacquelyn Trujillo, also an MSTP student, and Kurt Lu, the Eugene and Gloria Bauer Professor of Dermatology.

This work was supported by the National Institutes of Health Chemical Countermeasures Research Program executed by the National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institutes of Health Office of the Director under award number U54AR079795; and National Institutes of Health grant EY019463, EY032922, EY028560, EY036320, T32GM008152 and F31AR081685.

Here’s a link to and a citation for the paper,

A novel therapy to ameliorate nitrogen mustard-induced limbal stem cell deficiency using lipoprotein-like nanoparticles by Elif Kayaalp Nalbant, Timothy J. Feliciano, Aliakbar Mohammadlou, Vincent L. Xiong, Jacquelyn E. Trujillo, Andrea E. Calvert, Nihal Kaplan, Parisa Foroozandeh, Jayden Kim, Emma M. Bai, Xiaolin Qi, Fernando Tobias, Eric W. Roth, Vinayak P. Dravid, Kurt Q. Lu, SonBinh T. Nguyen, C. Shad Thaxton, Han Peng & Robert M. Lavker. j Regenerative Medicine volume 10, Article number: 14 (2025) DOI: https://doi.org/10.1038/s41536-025-00402-5 Published: 20 March 2025

This paper is open access.